A Comprehensive Pharmacological and Clinical Review of Trelagliptin (DB15323): The First Once-Weekly Oral DPP-4 Inhibitor

Executive Summary

Trelagliptin represents a significant advancement in the management of Type 2 Diabetes Mellitus (T2DM), distinguished primarily by its classification as the first orally administered, once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor. Developed by Takeda Pharmaceutical Company Limited, this small molecule drug offers a potent and highly selective mechanism for improving glycemic control. Its therapeutic effect is rooted in the inhibition of the DPP-4 enzyme, which potentiates the endogenous incretin system, leading to glucose-dependent enhancement of insulin secretion and suppression of glucagon release. The cornerstone of its unique weekly dosing regimen is a sophisticated pharmacokinetic and pharmacodynamic profile, characterized by a long elimination half-life and, more critically, a slow rate of dissociation from its target enzyme, ensuring sustained biological activity throughout the dosing interval.

A robust clinical development program, conducted predominantly in Asian populations, has established Trelagliptin's efficacy as non-inferior to daily-dosed DPP-4 inhibitors, both as a monotherapy and as part of combination regimens. Its safety profile is well-characterized and comparable to others in its class, with a low intrinsic risk of hypoglycemia and a notable absence of clinically significant pharmacokinetic drug-drug interactions, a key advantage in patients often requiring polypharmacy. Specific trials have confirmed its utility and defined dose adjustments for challenging patient populations, including those with severe renal impairment. Trelagliptin's market trajectory is as distinct as its pharmacology; following its first global approval in Japan, it has gained traction in several other Asian nations. Concurrently, a strategic business decision, driven by the economics of clinical development rather than clinical merit, led to the discontinuation of its pursuit of regulatory approval in the United States and European Union. This review provides an exhaustive analysis of Trelagliptin, synthesizing data on its chemical properties, pharmacological action, clinical evidence, and regulatory context to create a definitive resource on this important therapeutic agent.

Section 1: Chemical Identity and Physicochemical Properties

The foundational understanding of any pharmaceutical agent begins with its precise chemical identity and physical characteristics. These properties dictate its formulation, stability, and interaction with biological systems. Trelagliptin is a well-defined small molecule with a comprehensive set of identifiers and established physicochemical properties.

1.1 Nomenclature and Identifiers

Trelagliptin is identified by a variety of names and codes across scientific literature, regulatory filings, and commercial markets. Its generic name is Trelagliptin.[1] During its development by Takeda, it was primarily known by the research code SYR-472, with other codes such as YR-472, CS-926, and TAK-472 also being used.[1] Commercially, it is marketed under several brand names globally, including Zafatek® in Japan and China, Trelaglip® in India, Wedica® and Triliptin® in Bangladesh, Truli-1® in Kenya, Trelaget® in Pakistan, and TRELA® in Myanmar and Cambodia.[2]

For unambiguous identification in scientific and regulatory databases, a standardized set of identifiers is used. These are summarized in Table 1. The CAS Registry Number for the active free base is 865759-25-7, while the commonly formulated succinate salt is identified by CAS Number 1029877-94-8.[2]

Table 1: Key Identifiers and Physicochemical Properties of Trelagliptin

Property	Value	Source(s)
Generic Name	Trelagliptin	2
DrugBank ID	DB15323	2
CAS Number (free base)	865759-25-7	2
CAS Number (succinate)	1029877-94-8	5
Molecular Formula	C18​H20​FN5​O2​	2
Molar Mass	357.389 g·mol⁻¹	2
IUPAC Name	2-({6--3-methyl-2,4-dioxo-3,4-dihydro-1(2H)-pyrimidinyl}methyl)-4-fluorobenzonitrile	2
Appearance	White to off-white solid	9
Solubility	≥11.6 mg/mL in DMSO; ≥3.68 mg/mL in EtOH (with warming); ≥93.8 mg/mL in H₂O	9
Stability	≥ 4 years at -20°C	3

1.2 Molecular Structure and Properties

Trelagliptin is a synthetic small molecule with the chemical formula C18​H20​FN5​O2​ and a molar mass of approximately 357.39 g·mol⁻¹.[2] Chemically, it is classified as a member of the benzenes and a nitrile, containing a fluorobenzonitrile moiety.[8]

Structurally, Trelagliptin is a fluorinated derivative of alogliptin, another DPP-4 inhibitor developed by Takeda.[2] Both molecules share a common chiral center, the (R)-piperidin-3-amine moiety, which is critical for their interaction with the DPP-4 enzyme.[11] The structural distinction of Trelagliptin arises from the modification of the aromatic ring attached to the uracil core. This modification, the introduction of a fluorine atom and a cyano group, is not arbitrary but represents a deliberate medicinal chemistry strategy. The fluorination of drug candidates is a well-established technique to enhance metabolic stability by blocking sites susceptible to oxidative metabolism by cytochrome P450 (CYP) enzymes. This structural design choice is directly linked to Trelagliptin's enhanced chemical stability and resistance to metabolic degradation, which are foundational to its long-acting pharmacokinetic profile.[2] This strategic molecular engineering is a key reason why Trelagliptin exhibits minimal CYP-mediated metabolism, a property that underpins its long elimination half-life and suitability for once-weekly dosing.

Physically, Trelagliptin is a white to off-white solid that is stable for at least four years when stored appropriately.[3] It demonstrates good solubility in water and various organic solvents, as detailed in Table 1.[9] X-ray crystallography studies have elucidated its three-dimensional structure, providing precise data on its solid-state conformation. For one crystal structure, the Hermann-Mauguin space group symbol is P 1 21 1, with cell dimensions of a = 7.1057 Å, b = 7.8894 Å, and c = 15.5407 Å, and a β angle of 97.3250°.[8] This detailed structural information is vital for understanding its binding interactions at the molecular level and for quality control during manufacturing.

Section 2: Pharmacology and Mechanism of Action

The therapeutic utility of Trelagliptin stems from its precise and potent interaction with a key enzyme in glucose metabolism. Its pharmacology is defined by its class, its molecular mechanism, and the specific kinetics of its binding to the target enzyme, which collectively differentiate it from other agents in its class.

2.1 Therapeutic Class and Target Enzyme

Trelagliptin is an oral antidiabetic drug belonging to the therapeutic class of dipeptidyl peptidase-4 (DPP-4) inhibitors, a group of agents also known as "gliptins".[11] Its sole pharmacological target is the DPP-4 enzyme.[4] DPP-4 is a transmembrane glycoprotein and serine exopeptidase found on the surface of most cell types, where it is also known as the T-cell activation antigen CD26.[2] In the context of glucose homeostasis, DPP-4's primary role is the rapid inactivation of endogenous incretin hormones, which are released from the gut in response to food intake.[11] By cleaving these hormones, DPP-4 limits their biological activity, with the half-life of active glucagon-like peptide-1 (GLP-1) being less than five minutes.[11]

2.2 Molecular Mechanism of Action

The mechanism of action of Trelagliptin is centered on the potentiation of the incretin system. By inhibiting the enzymatic activity of DPP-4, Trelagliptin prevents the degradation of the two primary incretin hormones: GLP-1 and glucose-dependent insulinotropic polypeptide (GIP).[2] This inhibition leads to an increase in the circulating concentrations and prolongs the activity of these hormones.[15]

The elevated and sustained levels of active incretins result in several downstream physiological effects that collectively improve glycemic control, all of which occur in a glucose-dependent manner:

1. Enhanced Insulin Secretion: GLP-1 and GIP act on pancreatic β-cells to stimulate the synthesis and secretion of insulin. This effect is glucose-dependent, meaning insulin release is significantly augmented only when blood glucose levels are elevated, such as after a meal.[2]
2. Suppression of Glucagon Release: GLP-1 acts on pancreatic α-cells to suppress the secretion of glucagon. As glucagon is the primary hormone responsible for stimulating hepatic glucose production (gluconeogenesis and glycogenolysis), its suppression helps to lower both fasting and postprandial glucose levels.[2]

The glucose-dependency of these actions is a hallmark of the DPP-4 inhibitor class. It ensures that the drug's glucose-lowering effects are most pronounced when blood sugar is high and diminish as glucose levels approach normal, thereby conferring a very low intrinsic risk of causing hypoglycemia when Trelagliptin is used as a monotherapy.[2]

2.3 Binding Kinetics, Potency, and Selectivity

While all gliptins share the same general mechanism, Trelagliptin's clinical profile is defined by the specific characteristics of its interaction with the DPP-4 enzyme. It is a highly potent inhibitor, with an in vitro half-maximal inhibitory concentration (IC50​) against human DPP-4 reported to be 4 nM.[3] Comparative studies have shown it to be approximately 4-fold more potent than alogliptin and 12-fold more potent than sitagliptin, another widely used DPP-4 inhibitor.[16]

The binding of Trelagliptin to DPP-4 is characterized as reversible, competitive, and non-covalent.[16] However, its most distinguishing feature is its slow-binding kinetics, particularly its slow rate of dissociation from the enzyme-inhibitor complex. The dissociation half-life of Trelagliptin from the DPP-4 enzyme is approximately 30 minutes.[2] This is a direct consequence of its optimized molecular structure and its fit within the enzyme's active site. This prolonged engagement with the target enzyme is a critical factor that contributes to its sustained pharmacodynamic effect.

This slow dissociation rate is the molecular basis for Trelagliptin's long duration of action and is a key differentiator from other DPP-4 inhibitors. While a long plasma half-life contributes to maintaining drug concentrations, it is the sustained target engagement, enabled by the slow dissociation, that ensures the DPP-4 enzyme remains inhibited for an extended period, even as plasma drug levels decline. This sophisticated pharmacodynamic design underpins the viability of a once-weekly dosing schedule. The comparative binding kinetics, shown in Table 2, illustrate this advantage clearly.

Table 2: Comparative Binding Kinetics of Trelagliptin and Other DPP-4 Inhibitors

Drug	IC₅₀ (vs. human DPP-4)	Binding Type	Dissociation Half-life (t₁/₂)	Selectivity (vs. DPP-8/9)	Source(s)
Trelagliptin	4 nM	Reversible, Competitive, Slow-binding	~30 minutes	>10,000-fold	2
Alogliptin	~16 nM (4x less potent than Trelagliptin)	Reversible, Competitive	Not specified	High	16
Sitagliptin	~48 nM (12x less potent than Trelagliptin)	Reversible, Competitive	~3.5 minutes	High	2
Vildagliptin	Not specified	Reversible, Covalent (transient)	<2 minutes	Lower	2

Furthermore, Trelagliptin exhibits exceptional selectivity. It is over 10,000-fold more selective for DPP-4 than for related proteases such as DPP-8 and DPP-9.[3] This high degree of selectivity is crucial for minimizing the potential for off-target effects and contributes to its favorable safety profile.[14]

2.4 Pharmacodynamic Profile

The potent and sustained inhibition of the DPP-4 enzyme translates directly into a durable pharmacodynamic effect. Clinical studies have demonstrated that a standard 100 mg once-weekly dose of Trelagliptin maintains a mean DPP-4 inhibition of 77.4% even seven days after administration.[2] Long-term efficacy studies have confirmed that this level of inhibition, between 75% and 80%, is consistently maintained over a 52-week treatment period, providing stable, around-the-clock glycemic control.[17]

Beyond its primary effect on hemoglobin A1c (HbA1c) and fasting plasma glucose, Trelagliptin has been shown to reduce glycemic variability (GV).[2] By smoothing out the daily fluctuations in blood glucose and reducing postprandial hyperglycemic spikes, it may mitigate the glucotoxicity that contributes to vascular damage. This reduction in GV is considered a potential mechanism for lowering the long-term risk of microvascular and macrovascular complications in patients with diabetes.[2]

Additional preclinical data suggest that Trelagliptin may also have beneficial effects on insulin resistance. Studies in rat adipocytes have shown that it can increase glucose consumption by stimulating the translocation of the glucose transporter GLUT4 to the cell membrane. This effect may be linked to a reduction in the production of free fatty acids and resistin, both of which contribute to insulin resistance.[12] Some evidence also points to a beneficial impact on lipid profiles, with reductions in cholesterol and low-density lipoprotein observed.[12]

Section 3: Pharmacokinetic Profile (ADME)

The pharmacokinetic profile of a drug, encompassing its absorption, distribution, metabolism, and excretion (ADME), is a critical determinant of its dosing regimen, efficacy, and safety. Trelagliptin's ADME properties are characterized by predictable oral absorption, low protein binding, minimal metabolism, and primary renal excretion, with a long elimination half-life that forms the basis of its once-weekly administration.

3.1 Absorption and Distribution

Trelagliptin is administered orally in the form of an immediate-release tablet.[18] Following oral administration, it is absorbed from the gastrointestinal tract, with peak plasma concentrations (

Tmax​) generally reached within 4 to 6 hours.[14] A pharmacokinetic study conducted in healthy Egyptian volunteers reported a slightly faster mean

Tmax​ of 1.1 ± 0.34 hours.[19]

The absorption of Trelagliptin is not significantly affected by food. Clinical studies have shown that there are no clinically meaningful interactions with food, and its administration is not tied to meals.[20] One study that administered the drug after a meal noted a minor 16.8% increase in maximum concentration (

Cmax​) and a negligible 2.5% decrease in total exposure (AUC), confirming that it can be taken with or without food without requiring dose adjustment.[21]

Once absorbed into the systemic circulation, Trelagliptin exhibits low binding to plasma proteins, with a binding ratio of 22.1% to 27.6%.[21] This low level of protein binding suggests that a high fraction of the drug is free and available to interact with its target enzyme and distribute into tissues. With once-weekly dosing of 100 mg, Trelagliptin reaches steady-state plasma concentrations, ranging from 20.00 to 21.60 ng/mL, by the fourth week of treatment.[2]

3.2 Metabolism and Excretion

A defining feature of Trelagliptin's pharmacokinetic profile is its resistance to metabolic degradation. Metabolism via the cytochrome P450 (CYP) enzyme system is considered negligible.[20] This property, stemming from its fluorinated chemical structure, minimizes the potential for metabolic drug-drug interactions and contributes to its predictable clearance profile. While one source mentions the formation of an active metabolite (M-I) through N-demethylation, primarily mediated by CYP2D6, the overwhelming characteristic of the drug is its excretion in an unchanged form.[21]

The primary route of elimination for Trelagliptin is renal excretion.[20] Clinical pharmacology studies have shown that a high percentage of the administered dose is recovered as unchanged drug in the urine. Following a single oral dose, the cumulative urinary excretion rate over 168 hours (one week) was approximately 71% to 76%.[21]

This combination of low metabolism and high renal excretion results in a long elimination half-life (t1/2​), which is the key pharmacokinetic property enabling once-weekly dosing. The half-life has been reported as approximately 54.3 hours in some studies and within a range of 65 to 95 hours in others.[2] A study in Egyptian volunteers, which monitored plasma levels for 96 hours, reported a shorter half-life of 15.1 ± 1.6 hours, a difference that may be attributable to the shorter observation period or population-specific factors, though overall exposure was comparable to Japanese populations.[19]

In patients requiring renal replacement therapy, Trelagliptin is only modestly dialyzable. A standard 4-hour session of hemodialysis removes approximately 9.2% of the drug, indicating that dialysis is not an effective means of clearing the drug in cases of overdose or severe accumulation.[20]

3.3 Population Pharmacokinetics

Given its primary reliance on renal clearance, the pharmacokinetics of Trelagliptin are predictably and significantly influenced by a patient's renal function. This dependency has been a central focus of its clinical development and is a critical consideration in its clinical use. In patients with moderate renal impairment, the delayed excretion leads to increased blood concentrations of Trelagliptin, necessitating a dose reduction to 50 mg once weekly.[18] Initially, the drug was contraindicated in patients with severe renal impairment or end-stage renal disease (ESRD) due to the unknown safety implications of drug accumulation.[22] However, this knowledge gap prompted a dedicated clinical trial to be conducted in this specific population. The successful outcome of this trial established the safety and efficacy of a further reduced dose of 25 mg once weekly, leading to a revision of the drug's labeling in Japan to include specific dosing guidance for these patients, thereby expanding its clinical utility.[22] This progression from contraindication to evidence-based dosing recommendation exemplifies a rigorous, science-driven approach to drug development.

Conversely, studies comparing different ethnic populations have found no clinically significant differences in pharmacokinetics. A study directly comparing key parameters (Cmax​, Tmax​, and AUC) between healthy Egyptian and Japanese volunteers found the results to be closely related, leading to the conclusion that no dose modifications are necessary based on this ethnic difference.[19]

Table 3: Summary of Key Pharmacokinetic Parameters of Trelagliptin

Parameter	Value / Description	Comments / Context	Source(s)
Administration Route	Oral (immediate-release tablet)	Standard route of administration.	18
Tmax​ (Time to Peak)	1.1–6 hours	Time to reach maximum plasma concentration after a single dose.	14
Food Effect	Not clinically significant	Can be taken with or without food.	20
Plasma Protein Binding	22.1% – 27.6%	Low binding, high fraction of free drug available.	21
Primary Metabolism	Negligible	Metabolism via CYP450 system is minimal; highly resistant to degradation.	20
Primary Excretion Route	Renal	~71-76% of the drug is excreted unchanged in the urine over 168 hours.	20
Elimination Half-life (t1/2​)	~54–95 hours	Long half-life is a key contributor to the once-weekly dosing regimen.	2
Effect of Renal Impairment	Significant	Exposure increases as renal function declines. Dose reduction is required for moderate to severe impairment.	20
Dialyzability	Modest	Only ~9.2% is removed by a 4-hour hemodialysis session.	20

Section 4: Clinical Development and Efficacy

The clinical utility of Trelagliptin has been established through a comprehensive program of clinical trials, primarily conducted in Japan and other Asian countries. These studies have systematically evaluated its efficacy and safety across various clinical scenarios, from monotherapy to combination treatment and in special patient populations, solidifying its position as a valuable therapeutic option for T2DM.

4.1 Overview of Clinical Trial Program

Trelagliptin has been investigated in a full spectrum of clinical trials, from Phase I to post-marketing Phase IV studies.[23] The program was strategically designed not only to demonstrate the drug's fundamental glucose-lowering ability but also to establish its specific clinical niche, which is centered on convenience and applicability to challenging patient populations. Key trials have included placebo-controlled studies, active-comparator trials against daily DPP-4 inhibitors, long-term open-label extension studies, and targeted trials in patients with comorbidities like renal impairment.[17] Furthermore, large-scale, long-term observational surveys, such as NCT03555591 involving approximately 3000 patients in Japan, are ongoing to gather real-world evidence on its long-term safety and effectiveness in routine clinical practice.[28]

4.2 Efficacy in Monotherapy and Combination Therapy

Trelagliptin has demonstrated robust and sustained efficacy both as a standalone agent and when added to other oral antidiabetic drugs. In a pivotal 52-week, open-label, Phase 3 study conducted in Japanese patients, Trelagliptin 100 mg once weekly provided significant glycemic improvement.[17] As a monotherapy for patients inadequately controlled with diet and exercise, it resulted in a mean change in HbA1c from baseline of -0.57% at the end of the 52-week treatment period. The efficacy was also confirmed in various combination therapy arms, with mean HbA1c reductions ranging from -0.25% (when added to a glinide) to as much as -0.74% (when added to a thiazolidinedione).[17] These results confirm its utility as both a second-line add-on therapy, its typical use when metformin is insufficient, and as a first-line treatment for patients in whom metformin is contraindicated or not tolerated.[2]

4.3 Comparative Efficacy and Patient-Reported Outcomes

A critical component of Trelagliptin's clinical development was to demonstrate that its convenience did not come at the cost of efficacy. A key Phase 3, randomized, double-blind, active-controlled study was conducted to compare once-weekly Trelagliptin against the once-daily DPP-4 inhibitor alogliptin. The results showed that Trelagliptin was non-inferior to alogliptin in reducing HbA1c over 24 weeks, and it exhibited a comparable safety and tolerability profile.[11] This finding was crucial, as it established that patients could achieve equivalent glycemic control with a significantly reduced dosing frequency.

To provide clinicians with confidence in transitioning patients from existing daily therapies, an open-label, Phase 3 exploratory study was performed. This trial evaluated patients with stable glycemic control on daily sitagliptin who were switched to once-weekly Trelagliptin. The results showed that the switch could be made without any major adverse impact on glycemic control or safety, further supporting its integration into clinical practice.[32]

Recognizing that the primary advantage of Trelagliptin is patient convenience, specific studies were designed to evaluate patient-reported outcomes. A completed Phase IV trial (NCT03231709) directly assessed treatment preference for weekly versus daily DPP-4 inhibitors, and another (NCT03014479) evaluated the impact of Trelagliptin on patient quality of life.[27] This focus on the patient experience highlights a deliberate strategy to position Trelagliptin as a therapy that not only meets clinical endpoints but also reduces treatment burden.

4.4 Efficacy in Special Populations

The value of a therapeutic agent is often defined by its utility in difficult-to-treat patient populations. Trelagliptin was rigorously evaluated in patients with renal impairment, a common comorbidity in T2DM. A landmark Phase 3 study (NCT02512068) was conducted in patients with severe renal impairment (creatinine clearance <30 mL/min) or ESRD requiring hemodialysis.[23] In the 12-week, double-blind, placebo-controlled phase of this study, a reduced dose of Trelagliptin (25 mg once weekly) demonstrated superior efficacy over placebo. The least squares mean difference in HbA1c change from baseline was -0.72% (95% CI -0.966, -0.473; P < 0.0001), a result that is both statistically significant and clinically meaningful.[24] This efficacy was sustained for up to 52 weeks in the open-label extension phase, establishing Trelagliptin as a safe and effective treatment option for this high-risk population.[33]

Trelagliptin has also been proven effective as an add-on therapy for patients who are inadequately controlled on insulin. A Phase IV, randomized, placebo-controlled study in Japanese patients on stable insulin therapy found that the addition of Trelagliptin 100 mg once weekly resulted in a significant reduction in HbA1c compared to placebo after 12 weeks. The least squares mean difference was -0.63% (95% CI, -0.83 to -0.44; P < 0.0001). Importantly, this improved glycemic control was achieved without any episodes of severe hypoglycemia, demonstrating a favorable risk-benefit profile in this combination.[34]

Table 4: Summary of Efficacy Outcomes from Key Phase III/IV Clinical Trials

Study Identifier / Reference	Phase	Design	Patient Population	Treatment Arms	Duration	Primary Efficacy Outcome (Mean Change in HbA1c)	Source(s)
Non-inferiority vs. Alogliptin 11	III	Randomized, Double-blind, Active-controlled	T2DM patients	Trelagliptin 100 mg weekly vs. Alogliptin daily	24 weeks	Trelagliptin: -0.33% Alogliptin: -0.45% (Met non-inferiority criteria)	11
52-Week Monotherapy/Combination 17	III	Open-label, Long-term	T2DM patients on monotherapy or add-on	Trelagliptin 100 mg weekly (as monotherapy or add-on to various OADs)	52 weeks	Monotherapy: -0.57% Add-on: -0.25% to -0.74%	17
Severe Renal Impairment Study 24	III	Randomized, Double-blind, Placebo-controlled	T2DM with severe RI or ESRD	Trelagliptin 25 mg weekly vs. Placebo	12 weeks	Trelagliptin: -0.71% Placebo: +0.01% (LS Mean Difference: -0.72%; P < 0.0001)	24
Add-on to Insulin Study 34	IV	Randomized, Double-blind, Placebo-controlled	T2DM inadequately controlled on insulin	Trelagliptin 100 mg weekly + Insulin vs. Placebo + Insulin	12 weeks	Trelagliptin: Significant reduction (LS Mean Difference: -0.63%; P < 0.0001)	34
Switchover from Sitagliptin 32	III	Open-label, Exploratory	T2DM with stable control on daily sitagliptin	Switch to Trelagliptin 100 mg weekly	12 weeks	No marked change in blood glucose; maintained glycemic control.	32

Section 5: Safety, Tolerability, and Drug Interactions

A thorough evaluation of a drug's safety profile is paramount to its clinical use. Trelagliptin has been shown to be generally well-tolerated in clinical trials, with a safety profile consistent with the DPP-4 inhibitor class. Its interaction potential is characterized by a low risk of pharmacokinetic interactions but a predictable and manageable risk of pharmacodynamic interactions with other glucose-lowering agents.

5.1 Comprehensive Adverse Event Profile

Data from extensive clinical trials, including long-term studies of up to 52 weeks, indicate that Trelagliptin is well-tolerated.[17] The majority of adverse events (AEs) reported during these trials were of mild or moderate severity.[17] In a large 52-week study involving 680 patients, the most frequently reported treatment-emergent adverse event across all treatment arms was nasopharyngitis.[17] Other commonly reported AEs (with an incidence of ≥0.1% to <5%) include headache, upper respiratory tract infections, gastrointestinal discomfort, rash, and pruritus.[35] Laboratory abnormalities observed included elevations in liver enzymes (ALT, AST, γ-GTP), lipase, and amylase.[36] The overall incidence of AEs is comparable between Trelagliptin and other active comparators like alogliptin.[11]

5.2 Analysis of Key Safety Considerations

While generally safe, there are several key safety considerations associated with Trelagliptin, most of which are class effects common to all DPP-4 inhibitors.

• Hypoglycemia: Due to its glucose-dependent mechanism of action, Trelagliptin carries a low intrinsic risk of hypoglycemia when used as a monotherapy.[2] However, this risk is substantially increased when it is used in combination with agents that can independently cause hypoglycemia, particularly insulin secretagogues (e.g., sulfonylureas) or exogenous insulin.[12] In the 52-week long-term study, hypoglycemia was reported in only 1.8% of all patients, but the incidence was highest in the group receiving combination therapy with a sulfonylurea (4.4%).[17] To mitigate this pharmacodynamic interaction, a reduction in the dosage of the concomitant sulfonylurea or insulin should be considered when initiating Trelagliptin.[20]
• Acute Pancreatitis: Cases of acute pancreatitis have been reported in postmarketing surveillance for Trelagliptin and are a known, albeit rare, risk associated with the DPP-4 inhibitor class.[20] Patients should be observed for signs and symptoms of pancreatitis, such as persistent, severe abdominal pain, which may or may not be accompanied by vomiting. If pancreatitis is suspected, Trelagliptin should be promptly discontinued and appropriate medical management initiated.[20]
• Cardiovascular Safety and QT Prolongation: Extensive clinical trial data have not identified any significant cardiovascular risk associated with the therapeutic use of Trelagliptin.[18] A thorough QT/QTc study was conducted to assess its proarrhythmic potential. While no effect was seen at therapeutic or moderately supratherapeutic doses (200 mg), a QT interval prolongation was observed at a very high dose of 800 mg.[20] This indicates a wide safety margin, and proarrhythmic risk is not considered a clinical concern at the recommended 100 mg weekly dose.
• Other Considerations: Rare cases of intestinal obstruction have been reported with DPP-4 inhibitors and are listed as a potential serious adverse effect.[38] Patients with a history of laparotomy or bowel obstruction should be monitored. Hypersensitivity reactions, such as rash and pruritus, can also occur.[36]

5.3 Interaction Profile

Trelagliptin's interaction profile is a key clinical feature, notable for its lack of pharmacokinetic interactions. This is a direct result of its minimal reliance on the CYP450 enzyme system for metabolism. In vitro studies have confirmed that Trelagliptin does not inhibit or induce major CYP450 isoforms at clinically relevant concentrations.[20] This has been verified in vivo through clinical interaction studies which demonstrated that Trelagliptin had no clinically relevant effect on the pharmacokinetics of substrates for CYP1A2, CYP2C9, CYP2D6, and CYP3A4.[20] Furthermore, co-administration with metformin or glimepiride did not alter the pharmacokinetics of Trelagliptin.[20] This "clean" pharmacokinetic profile is a significant advantage, particularly in the T2DM patient population, which is often elderly and subject to polypharmacy for managing comorbidities.

There are also no clinically meaningful interactions with food. Trelagliptin can be administered without regard to meals, offering flexibility to patients.[20]

5.4 Contraindications, Warnings, and Precautions

The use of Trelagliptin is contraindicated in patients with a known history of hypersensitivity to the drug or any of its components.[35] It is also contraindicated for the treatment of Type 1 diabetes mellitus or diabetic ketoacidosis, as its mechanism of action is dependent on endogenous insulin production.[29]

Initially, Trelagliptin was contraindicated in Japan for patients with severe renal impairment or ESRD.[22] However, following the completion of a dedicated study (SYR-472-3003), this contraindication was removed, and specific dose adjustments (25 mg weekly) are now recommended for this population.[22] A dose reduction to 50 mg weekly is recommended for patients with moderate renal impairment.[18]

Table 5: Incidence of Common Adverse Events from the 52-Week Phase 3 Study

Adverse Event	Trelagliptin Monotherapy (n=248) [%]	Combination with Sulfonylurea (n=158) [%]	Combination with Biguanide (n=70) [%]	Overall (n=680) [%]
Any TEAE	79.8	87.3	64.3	80.4
Nasopharyngitis	41.5	46.2	34.3	40.7
Hypoglycemia	0.4	4.4	0.0	1.8
Constipation	4.0	5.1	5.7	4.6
Eczema	4.0	3.2	1.4	3.5
Gastroenteritis	3.2	3.8	4.3	3.4
Back Pain	2.0	3.8	5.7	3.1
Data adapted from the 52-week open-label study in Japanese patients with T2DM.17 TEAE: Treatment-Emergent Adverse Event.

Section 6: Regulatory History and Market Context

The global availability and clinical adoption of a drug are shaped not only by its scientific and clinical merits but also by regulatory processes, commercial strategy, and intellectual property considerations. Trelagliptin's journey to market is a compelling example of these intersecting forces, resulting in a distinct geographical footprint concentrated in Asia.

6.1 Development and Global Approvals

Trelagliptin was discovered and developed by Takeda Pharmaceutical Company Limited.[41] Following a comprehensive clinical development program, Takeda submitted a New Drug Application to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). On March 26, 2015, the Japanese Ministry of Health, Labour and Welfare (MHLW) granted marketing approval for Zafatek® (trelagliptin succinate) for the treatment of type 2 diabetes.[5] This marked the first global approval for Trelagliptin and its debut as the world's first once-weekly oral DPP-4 inhibitor.[31] The approval was based on the positive safety and efficacy results from multiple Phase III clinical studies conducted in Japanese patients.[41]

Following its launch in Japan, Trelagliptin has seen its approval and marketing expand to several other key Asian markets. It has been approved by the Central Drugs Standard Control Organisation (CDSCO) in India and is also available in China, Bangladesh, Pakistan, and other nations in the region.[6] This expansion has solidified its position as an important treatment option for T2DM across Asia.

6.2 Strategic Discontinuation in US/EU Markets

Despite its successful clinical profile and approval in Japan, Trelagliptin has not been approved for use in the United States or the European Union. In 2014, Takeda announced the strategic decision to discontinue Phase III development of the drug in these major Western markets.[42]

This decision was not a reflection of any safety or efficacy concerns. Instead, it was a direct consequence of the commercial and contractual terms associated with its development. The licensing rights for the DPP-4 inhibitor class, which Takeda had acquired from Furiex Pharmaceuticals, included a specific clause that mandated Takeda to purchase all clinical trial services for Phase II and Phase III studies conducted in the US and EU exclusively through Furiex.[2] Takeda ultimately concluded that the costs quoted by Furiex for these services were prohibitively high, making the pursuit of regulatory approval in these markets financially unviable.[2]

This business decision has had a profound impact on the drug's global trajectory. A scientifically sound and clinically valuable molecule, which successfully completed Phase II trials in the West, was prevented from reaching patients in these large markets due to the economics of its development contract. This situation serves as a powerful case study on how non-clinical factors can dictate the availability of new medicines. Takeda's subsequent pivot to focus on Asian markets created a unique market dynamic, opening opportunities for regional pharmaceutical companies. For instance, Zuventus Healthcare in India undertook its own development of the active pharmaceutical ingredient (API) and conducted local clinical trials to secure approval and bring Trelagliptin to the Indian market, demonstrating how global strategic decisions can foster regional innovation and manufacturing capabilities.[6]

Section 7: Synthesis and Pharmaceutical Formulation

The translation of a chemical entity into a safe and effective medication involves a controlled chemical synthesis process and a stable, bioavailable pharmaceutical formulation.

7.1 Chemical Synthesis Pathway

The chemical synthesis of Trelagliptin is a multi-step process that has been described in the literature. The synthesis typically begins with 4-fluoro-2-methylbenzonitrile. This starting material undergoes bromination to yield 2-bromomethyl-4-fluorobenzonitrile. This intermediate is then condensed with 3-methyl-6-chlorouracil. The final and most critical step in the synthesis is a nucleophilic substitution reaction where the resulting intermediate is combined with unprotected (R)-3-aminopiperidine. This step is crucial for achieving high regioselectivity and forming the final Trelagliptin molecule with the correct stereochemistry.[12]

7.2 Formulation and Dosage Forms

For pharmaceutical use, Trelagliptin is formulated as a succinate salt: trelagliptin succinate (C18​H20​FN5​O2​⋅C4​H6​O4​), which has a molecular weight of 475.47 g·mol⁻¹.[18] This salt form is prepared by dissolving the crude Trelagliptin free base along with succinic acid in a solvent like isopropyl alcohol, followed by recrystallization to yield a high-purity, stable product.[12]

The final drug product is an immediate-release, film-coated tablet designed for oral administration.[18] The tablets are available in multiple strengths to accommodate different clinical needs, particularly for dose adjustments in patients with renal impairment. The available dosage strengths are 25 mg, 50 mg, and 100 mg.[18] The standard adult dosage is 100 mg administered once weekly, while the 50 mg and 25 mg strengths are used for patients with moderate and severe renal impairment, respectively.[6]

Section 8: Conclusion and Future Perspectives

Trelagliptin has firmly established itself as a distinct and valuable agent in the therapeutic armamentarium for Type 2 Diabetes Mellitus. Its clinical profile is the result of intentional molecular design, a strategic clinical development program, and a unique market trajectory.

Synthesizing the extensive body of evidence, Trelagliptin is best characterized as a potent, highly selective DPP-4 inhibitor whose defining feature is a sophisticated pharmacodynamic profile. This profile, driven by a slow dissociation rate from the DPP-4 enzyme, enables a sustained biological effect that supports a convenient and effective once-weekly oral dosing regimen. Its clinical efficacy has been proven to be non-inferior to that of standard daily-dosed DPP-4 inhibitors, providing robust glycemic control both as a monotherapy and in combination with other antidiabetic agents. The safety profile of Trelagliptin is well-characterized and manageable. It is marked by a low risk of pharmacokinetic drug-drug interactions due to its minimal CYP450 metabolism, a significant advantage for patients on polypharmacy. This is balanced by a predictable pharmacodynamic risk of hypoglycemia, which requires clinical vigilance and potential dose adjustments when used with insulin or sulfonylureas.

The primary clinical value of Trelagliptin lies in its potential to significantly improve medication adherence, a cornerstone of effective chronic disease management. By reducing the dosing frequency from 365 times per year to just 52, it substantially lessens the treatment burden on patients. This convenience can foster better long-term adherence, which may translate into more consistent glycemic control and a reduced risk of long-term diabetic complications. Furthermore, its proven efficacy and established dosing regimen in patients with severe renal disease and ESRD provide a crucial and reliable treatment option for a particularly vulnerable and difficult-to-treat patient population.

Looking ahead, the journey of Trelagliptin is far from over. While its market is currently concentrated in Asia, the ongoing collection of real-world evidence from Phase IV studies and large-scale post-marketing surveillance will be critical for further defining its long-term safety, durability of effect, and effectiveness in diverse, real-world patient populations.[6] Future research should continue to explore its potential ancillary benefits. The demonstrated ability to reduce glycemic variability warrants further investigation into its impact on cardiovascular outcomes. Additionally, early preclinical signals suggesting potential neuroprotective and anti-inflammatory effects could open new avenues of research, potentially expanding its therapeutic utility beyond glycemic control.[43] Trelagliptin stands as a testament to how targeted pharmacodynamic design can translate into meaningful clinical innovation, improving both efficacy and the patient experience.

Works cited

1. trelagliptin - Drug Central, accessed September 8, 2025, https://drugcentral.org/drugcard/5013
2. Trelagliptin - Wikipedia, accessed September 8, 2025, https://en.wikipedia.org/wiki/Trelagliptin
3. Trelagliptin (SYR-472, CAS Number: 865759-25-7) | Cayman Chemical, accessed September 8, 2025, https://www.caymanchem.com/product/18504/trelagliptin
4. Trelagliptin | 99.97%(HPLC) | In Stock | DPP inhibitor - Selleck Chemicals, accessed September 8, 2025, https://www.selleckchem.com/products/trelagliptin.html
5. Trelagliptin - New Drug Approvals, accessed September 8, 2025, https://newdrugapprovals.org/2016/02/25/trelagliptin-2/
6. Introducing a Novel Once-weekly Dipeptidyl Peptidase 4 Inhibitor: Trelagliptin in India - JAPI, accessed September 8, 2025, https://www.japi.org/article/japi-73-8-85
7. Trelagliptin free base | SYR-472 | CAS#865759-25-7 | 1029877-94-8 - MedKoo Biosciences, accessed September 8, 2025, https://www.medkoo.com/products/5035
8. Trelagliptin | C18H20FN5O2 | CID 15983988 - PubChem, accessed September 8, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Trelagliptin
9. Trelagliptin | 865759-25-7 - ChemicalBook, accessed September 8, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB52628490.htm
10. Trelagliptin|DPP-4 inhibitor,long-acting and selective - APExBIO, accessed September 8, 2025, https://www.apexbt.com/trelagliptin.html
11. Trelagliptin – Knowledge and References - Taylor & Francis, accessed September 8, 2025, https://taylorandfrancis.com/knowledge/Medicine_and_healthcare/Pharmaceutical_medicine/Trelagliptin/
12. Trelagliptin Succinate: Key Facts & Uses - Bulat Pharmaceutical, accessed September 8, 2025, https://bulatpharmaceutical.com/blog/everything-you-need-to-know-about-trelagliptin-succinate/
13. What is the mechanism of Trelagliptin Succinate? - Patsnap Synapse, accessed September 8, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-trelagliptin-succinate
14. What is Trelagliptin Succinate used for? - Patsnap Synapse, accessed September 8, 2025, https://synapse.patsnap.com/article/what-is-trelagliptin-succinate-used-for
15. en.wikipedia.org, accessed September 8, 2025, https://en.wikipedia.org/wiki/Trelagliptin#:~:text=It%20works%20by%20prolonging%20the,out%20daily%20blood%20glucose%20fluctuations.
16. Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for ..., accessed September 8, 2025, https://pubmed.ncbi.nlm.nih.gov/27328054/
17. (PDF) Long-term safety and efficacy of a novel once-weekly oral ..., accessed September 8, 2025, https://www.researchgate.net/publication/294425750_Long-term_safety_and_efficacy_of_a_novel_once-weekly_oral_trelagliptin_as_monotherapy_or_in_combination_with_an_existing_oral_antidiabetic_drug_in_patients_with_type_2_diabetes_mellitus_A_52-week_open
18. February 5, 2015 Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau Ministry of Health, Labour and Welfare, accessed September 8, 2025, https://www.pmda.go.jp/files/000213963.pdf
19. Investigation of Pharmacokinetic Parameters of Trelagliptin in Egyptian Volunteers Using Sensitive LC-MS/MS: A Comparative Study with a Japanese Population - PMC, accessed September 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8677398/
20. ndi.fda.moph.go.th, accessed September 8, 2025, https://ndi.fda.moph.go.th/uploads/drug_detail_corporation/doc/word/805/1330e56852e1efc924102c4c3eaad4a4-a1.pdf
21. Trelaget Leaflet PAK | Getz Pharma, accessed September 8, 2025, https://getzpharma.com/wp-content/uploads/2025/01/Trelaget-Leaflet-PAK.pdf
22. Report on Investigation Results, accessed September 8, 2025, https://www.pmda.go.jp/files/000231402.pdf
23. Trelagliptin Completed Phase 3 Trials for Type 2 Diabetes Mellitus Treatment - DrugBank, accessed September 8, 2025, https://go.drugbank.com/drugs/DB15323/clinical_trials?conditions=DBCOND0029752&phase=3&purpose=treatment&status=completed
24. Efficacy and safety of trelagliptin in Japanese patients with type 2 diabetes with severe renal impairment or end-stage renal disease: Results from a randomized, phase 3 study - PubMed, accessed September 8, 2025, https://pubmed.ncbi.nlm.nih.gov/31389201/
25. Investigation of Pharmacokinetic Parameters of Trelagliptin in Egyptian Volunteers Using Sensitive LC-MS/MS: A Comparative Study with a Japanese Population - ResearchGate, accessed September 8, 2025, https://www.researchgate.net/publication/356913772_Investigation_of_Pharmacokinetic_Parameters_of_Trelagliptin_in_Egyptian_Volunteers_Using_Sensitive_LC-MSMS_A_Comparative_Study_with_a_Japanese_Population
26. Diabetes Mellitus Unknown Status Phase 4 Trials for Trelagliptin (DB15323) - DrugBank, accessed September 8, 2025, https://go.drugbank.com/indications/DBCOND0027886/clinical_trials/DB15323?phase=4&status=unknown_status
27. Trelagliptin Completed Phase 4 Trials for Type 2 Diabetes Mellitus Treatment - DrugBank, accessed September 8, 2025, https://go.drugbank.com/drugs/DB15323/clinical_trials?conditions=DBCOND0029752&phase=4&purpose=treatment&status=completed
28. Type II Diabetes Mellitus Completed Phase Trials for Trelagliptin (DB15323) - DrugBank, accessed September 8, 2025, https://go.drugbank.com/indications/DBCOND0034269/clinical_trials/DB15323?status=completed
29. Specified Drug-Use Survey of Trelagliptin Tablets - ClinConnect, accessed September 8, 2025, https://clinconnect.io/trials/NCT03555591
30. Long‐term safety and efficacy of a novel once‐weekly oral trelagliptin as monotherapy or in combination with an existing oral antidiabetic drug in patients with type 2 diabetes mellitus: A 52‐week open‐label, phase 3 study - PMC - PubMed Central, accessed September 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5009134/
31. First novel once-weekly DPP-4 inhibitor, trelagliptin, for the treatment of type 2 diabetes mellitus - PubMed, accessed September 8, 2025, https://pubmed.ncbi.nlm.nih.gov/26523434/
32. Efficacy and safety of once-weekly oral trelagliptin switched from once-daily dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: An open-label, phase 3 exploratory study - PubMed, accessed September 8, 2025, https://pubmed.ncbi.nlm.nih.gov/28836351/
33. Efficacy and safety of trelagliptin in Japanese patients with type 2 diabetes with severe renal impairment or end‐stage renal disease: Results from a randomized, phase 3 study - ProQuest, accessed September 8, 2025, https://search.proquest.com/openview/f3ca6ad363038f97d5253fa396eb2876/1?pq-origsite=gscholar&cbl=1006415
34. Efficacy and safety of trelagliptin in combination with insulin therapy in Japanese patients with type 2 diabetes: Results from a randomized, Phase IV study - PubMed, accessed September 8, 2025, https://pubmed.ncbi.nlm.nih.gov/29862617/
35. Trelagliptin 50 mg Tablet (TRELAQWK 50) – Uses, Dosage & Side Effects - Steris Online, accessed September 8, 2025, https://www.sterisonline.com/blog/trelagliptin-50-mg-dose-uses-side-effects-amp-why-trelaqwk-50-is-a-smart-choice
36. ZAFATEK® (Trelagliptin) 100 mg film-coated tablets - National Drug Information, accessed September 8, 2025, https://ndi.fda.moph.go.th/uploads/drug_detail_corporation/doc/word/1163/ed9742f5fadc476ef5f180896cc0e95d-a1.pdf
37. Trelagliptin-100 - CYNO Pharmaceuticals, accessed September 8, 2025, https://www.cyno.co.in/trelagliptin-100/
38. Zafatek Tablets 50mg | Kusuri-no-Shiori(Drug Information Sheet), accessed September 8, 2025, https://www.rad-ar.or.jp/siori/english/search/result?n=44710
39. SKM Summary of Product Characteristics for Pharmaceutical Products 1. Name of the medicinal product: TRULI-1 50MG TABLETS 2. Qua, accessed September 8, 2025, https://products.pharmacyboardkenya.org/uploads/CTD9976_TRULI-L_50MG_TABLETS_SMPC.pdf
40. Trelagliptin 100 mg: Uses, Dosage, Side Effects & Weekly Diabetes Control - Steris Online, accessed September 8, 2025, https://www.sterisonline.com/blog/trelagliptin-100-mg-uses-dosage-side-effects-amp-weekly-diabetes-control
41. New Drug Application Approval of Zafatek® Tablets for the treatment of Type 2 Diabetes in Japan - Takeda Pharmaceuticals, accessed September 8, 2025, https://www.takeda.com/newsroom/newsreleases/2015/new-drug-application-approval-of-zafatek-tablets-for-the-treatment-of-type-2-diabetes-in-japan/
42. Trelagliptin: First Global Approval - PubMed, accessed September 8, 2025, https://pubmed.ncbi.nlm.nih.gov/26115728/
43. Trelagliptin Path: From regulatory setbacks in the west to approval in India - ResearchGate, accessed September 8, 2025, https://www.researchgate.net/publication/390314860_Trelagliptin_Path_From_regulatory_setbacks_in_the_west_to_approval_in_India
44. Trelagliptin: Chemical properties and synthesis to clinical efficacy and safety - Journal of Medicinal and Nanomaterials Chemistry, accessed September 8, 2025, https://jmnc.samipubco.com/article_216339_230ec825a92656a6529a8301826096b1.pdf